

SURGICAL MANAGEMENT OF PROLACTINOMAS

Thesis

Submitted for partial fulfillment of Medical Doctorate Degree in
NEUROSURGERY

By

HAZEM HASSAN HAMID

Assistant Lecturer of Neurosurgery
Faculty of Medicine, Beni -Suif University

Under supervision of

PROF. DR. ESSAM M. RASHAD EL-GAHAWY

*Professor of Neurosurgery
Faculty of Medicine, Cairo University*

PROF. DR. IBRAHIM MOHAMED IBRAHIM

*Professor of Neurosurgery
Faculty of Medicine, Cairo University*

DR. MOHAMED MAMDOUH SALAMA

*Assistant Professor of Neurosurgery
Faculty of Medicine, Cairo University*

DR. MOHAMED AHMED HEWEDY

*Lecturer of Neurosurgery
Faculty of Medicine, Beni Suif University*

FACULTY OF MEDICINE

CAIRO UNIVERSITY

2015

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

ACKNOWLEDGMENT

First of all, I must thank **ALLAH** "the most gracious and the most merciful.

*I am so greatly indebted to **Professor Dr. ESSAM M. RASHAD EL-GAHAWY**, Professor of Neurosurgery, Faculty of Medicine, Cairo University, for his fruitful advice and guidance, and under his supervision I had the honor to proceed with this work.*

*I also owe **Professor Dr. IBRAHIM MOHAMED IBRAHIM**, Professor of Neurosurgery, Faculty of Medicine, Cairo University, many thanks for his generous, kind and sincere advice to write this work.*

*I am also indebted to **Dr. MOHAMED MAMDOUH SALAMA**, Assistant Professor of Neurosurgery, Faculty of Medicine, Cairo University, for his great help and encouragement, guidance, and kindness.*

*Special thanks and gratitude are due to **Dr. MOHAMED AHMED HEWEDY**, Lecturer of Neurosurgery, Faculty of Medicine, Beni Suif University; his fruitful modifications have led to the proper accomplishment of this work.*

Last but not least I would like to extend my thanks to my parents and family who supported me a lot in producing this work.

ABSTRACT

Medical therapy is the treatment of choice for prolactinomas, with surgery reserved for certain patients. Current surgical indications for prolactinomas were studied. Indications of surgery, clinical outcome, biochemical cure, and extent of resection were assessed in 30 patients. Main indications included failed medical treatment and marked diminution of vision. Biochemical cure was obtained in half of patients particularly those with smaller tumors. Surgery in indicated patients achieves visual improvement and good remission rates particularly in patients with microadenomas or intrasellar macroadenomas, with low rate of complications.

KEYWORDS:

Surgical Management
Prolactinomas
Microadenomas
Macroadenomas

CONTENTS

▪ ACKNOWLEDGMENT	iii
▪ ABSTRACT	iv
▪ LIST OF ABBREVIATIONS	vi
▪ LIST OF FIGURES	viii
▪ LIST OF TABLES	x
▪ INTRODUCTION	1
▪ AIM OF THE WORK	3
▪ REVIEW OF THE LITERATURE	4
➤ Anatomy	4
➤ Pathophysiology	17
➤ Pathology	21
➤ Clinical Manifestation	28
➤ Diagnosis	34
➤ Differential Diagnosis	42
➤ Management	45
▪ PATIENTS AND METHOD	73
▪ RESULTS	76
▪ CASE PRESENTATIONS	88
▪ DISCUSSION	93
▪ CONCLUSION	104
▪ SUMMARY	105
▪ REFERENCES	107
▪ ARABIC SUMMARY	122

LIST OF ABBREVIATIONS

µgm	Microgram per litre
µIu	Micro international unit.
ACTH	Adreno-corticotropic hormone.
ADC	Apparent diffusion coefficient
ADH	Antidiuretic hormone.
CCF	Carotid cavernous fistula
cm	Centimeter
CSF	Cerebrospinal fluid.
CT	Computerized tomography.
D1	Type 1 Dopamine receptors.
D2	Type 2 Dopamine receptors.
DA	Dopamine Agonist.
DI	Diabetes insipidus
DNA	Deoxy nucleic acid.
EM	Electron Microscope.
ER	Estrogen Receptor.
FSH	Follicle stimulating hormone.
GABA	Gamma amino butyric acid.
GAP	Gonadotrophin associated peptide
GH	Growth hormone.
GK	Gamma Knife.
GnRH	Gonadotropin releasing hormone.
GY	Gray(joule per kilogram)
ICA	Internal Carotid Artery
IGF-1	Insulin like growth factor number 1.
IgG	Immunoglobulin G
LH	Luteinizing hormone.
LINAC	Linear accelerator.
MEN-1	Multiple endocrinal neoplasia type 1.
mg	Milligram
mIU/ml	Milli international unit per millilitre.

ml	Millilitre
MRA	Magnetic resonance angiography.
MRI	Magnetic Resonance Imaging.
mRNA	Messenger Ribonucleic Acid
MV	Megavolt
ng/ml	Nanogram per millilitre.
No.	Number.
NSGs	Non secretory granules
PIF	Prolactin inhibitory factor.
Pit	pituitary-specific transcription factor.
PL	Perception of light
PRL	Prolactin.
Pt	Patient.
PTTG	Pituitary tumor transforming gene.
SIADH	Syndrome of Inappropriate Antidiuretic Hormone secretion
SRS	stereotactic radio surgery.
T1WI	Weighted images.
T2WI	Weighted images.
TRH	Thyrotropin releasing hormone.
TSH	Thyroid stimulating hormone.
VIP	Vasoactive intestinal peptide.

LIST OF FIGURES

No.	TITLE	PAGE
1	Anatomy of the sphenoid bone: superior view	7
2	Anatomy of the sphenoid bone: conchal type sphenoid bone	8
3	Cavernous sinus	10
4	Intercavernous venous connections	10
5	The third ventricle	11
6	Anterior incisural space	12
7	Position of the optic chiasm	14
8	Vascular relationships in the suprasellar area	15
9	Relationships in the sellar and suprasellar areas. inferior view	16
10	Microscopic picture of prolactinoma, with immunohistochemical reaction for PRL	27
11	Electron Microscopic picture of prolactinoma, showing secretory granules	27
12	Microprolactinoma. On coronal SE T1-weighted image (a) the pituitary adenoma is hypointense compared with the unaffected anterior pituitary. On coronal TurboSE T2-weighted image (b) the signal of the lesion is very high	37
13	Early-phase dynamic gadolinium-enhanced coronal T1-WI showing a small well-defined ovoid microadenoma (arrow), which enhances less than the surrounding pituitary gland	38
14	Coronal gadolinium-enhanced T1-WI showing a large heterogeneously enhancing macroadenoma with suprasellar extension	39
15	Coronal gadolinium enhanced T1-WI. There is a heterogeneously enhancing sellar/parasellar lesion with encasement of the right carotid artery (arrowhead) indicating cavernous sinus invasion	39
16	Microscopic transsphenoid approach	58
17	Endoscopic view of sphenoid sinus and the dura lining the sella	59
18	The ‘gasket seal’ closure. A fascia lata overlay and a Medpore implant forming the watertight seal	60
19	Subfrontal exposure of the suprasellar region	62
20	Age distribution	76
21	Sex incidence	77

LIST OF FIGURES

No.	TITLE	PAGE
22	Distribution of size of adenoma related to sex distribution	78
23	Incidence of clinical manifestations	79
24	Distribution of prolactin level	80
25	Distribution of size of adenoma	81
26	Indications of surgery	82
27	Surgical approaches	83
28	Post-operative complications	86
29	Neuro-image of case no.1	88
30	Neuro-image of case no.2 (preoperative)	
31	Neuro-image of case no.2 (postoperative)	89
32	Neuro-image of case no. 3 (preoperative)	90
33	Neuro-image of case no. 3 (postoperative)	91
34	Neuro-image of case no. 4 (preoperative)	92
35	Neuro-image of case no. 4 (postoperative)	92

LIST OF TABLES

No.	TITLE	PAGE
1	Clinicopathological classification and incidence of pituitary adenomas	23
2	Dopamine agonists commonly used in the treatment of hyperprolactinaemia	51
3	Summary of surgical indications for prolactinomas	55
4	Surgical Approaches for Pituitary Tumors	56
5	Age incidence	76
6	Distribution of size of adenoma related to sex distribution	77
7	Incidence of clinical manifestations	79
8	Distribution of prolactin level	80
9	Correlation between size of adenoma & preoperative prolactin level	80
10	Distribution of size of adenoma and invasion	81
11	Indications of surgery	82
12	Surgical approaches	83
13	Postoperative serum prolactin level	84
14	Extent of surgical resection	85
15	Post-operative complications	86
16	The rates of gross total resection of endoscopic and microscopic surgery in many series	101

INTRODUCTION

INTRODUCTION

Prolactinomas are the most common hormone-secreting pituitary adenomas, representing approximately 30% of all pituitary tumors, and 50-60% of functioning adenomas⁽¹⁾.

Prolactinomas usually present with clinical manifestations of hyperprolactinoma as menstrual disturbances and/or galactorrhea in females, and loss of libido or impotence in males. Symptoms due to mass effect arise from tumor compression on adjacent structures causing diminution of vision or visual field defect, panhypopituitarism, and cranial nerves palsy⁽²⁾. Pituitary apoplexy can cause rapid enlargement of the tumor mass, leading to hypopituitarism and acute compression of sellar and parasellar structures⁽³⁾.

Diagnosis of prolactinoma requires, in addition to the clinical diagnosis, laboratory documentation of the presence of sustained hyperprolactinaemia and radiological evaluation by magnetic resonance imaging (MRI) or computed tomography (CT) showing the tumor and its relation to surrounding structures⁽⁴⁾.

The aim of treatment is to decrease the high level of prolactin with its consequent clinical symptoms, reduce the size of tumor and its mass effect, and to preserve the residual pituitary function. Treatment options include medical treatment with dopamine agonists, surgical excision, and radiation treatment⁽⁵⁾.

Medical treatment is considered the first line of therapy being effective in normalizing serum prolactin levels, shrinking the tumor mass, and restoring gonadal function⁽⁶⁾. Surgery is considered the second line of treatment being indicated in patients with failed medical treatment, patients not tolerating or refusing medical treatment by dopamine agonist, patients with marked diminution of vision, and some patients with apoplexy who need urgent decompression^(7,8). Radiation therapy including radiosurgery is

rarely required to treat prolactinomas, and is associated with a significant incidence of major side-effects, particularly hypopituitarism and damage to the optic apparatus⁽⁴⁾.

AIM OF THE WORK